International Journal of Hematology

, Volume 79, Issue 5, pp 465–471 | Cite as

Primary Mediastinal Large B-Cell Lymphoma: A Single-Institution Clinical Study in Japan

  • Naohiro Sekiguchi
  • Junko Nishimoto
  • Kazuki Tanimoto
  • Shigeru Kusumoto
  • Yasushi Onishi
  • Takashi Watanabe
  • Yukio Kobayashi
  • Hisao Asamura
  • Yoshikazu Kagami
  • Yoshihiro Matsuno
  • Kensei Tobinai


Several clinicopathologic studies of primary mediastinal large B-cell lymphoma (Med-DLBCL) have been reported from Western countries; however, only a few series of at most 10 cases are available in Japan.To further clarify the Med-DLBCL occurring in Japan, we analyzed the clinical features of 28 patients with Med-DLBCL diagnoses who were treated at the National Cancer Center Hospital between 1982 and 2002. The median age was 37 years (range, 18–80 years). The ages of 16 male patients ranged widely from 18 to 80 years, whereas the 12 female patients appeared to show a single age peak at 20 to 40 years. Only 13 patients (46%) achieved a complete response with initial treatments, mostly by CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine [Oncovin], and prednisolone) followed by radiotherapy.The estimated 3-year overall and failure-free survival rates were 32% and 33%, respectively, indicating the relatively unfavorable prognosis of the patients in our series.The following factors were found to be significantly associated with shortened survival prospects: age >60 years, serum lactate dehydrogenase level greater than normal, performance status >1, and presence of bulky mediastinal mass. In conclusion, the clinical features of Japanese patients with Med-DLBCL may be different from those with the disease in Western countries. Because this investigation was a single-institution study with a limited number of patients, however, multicenter confirmatory studies are needed.

Key words

Primary mediastinal large B-cell lymphoma Japan Geographical variation Treatment Prognostic factor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood. 1994;84:1361–1392.Google Scholar
  2. 2.
    Banks PM, Warnke RA. Mediastinal (thymic) large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology & Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:175–176.Google Scholar
  3. 3.
    Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997;15:1646–1653.CrossRefPubMedGoogle Scholar
  4. 4.
    Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared 916 nonmediastinal large B-cell lymphomas: a GELA (“Groupe d’Etude des lymphomas de I’Adulte”) study. Am J Surg Pathol. 1996;20:877–888.CrossRefPubMedGoogle Scholar
  5. 5.
    Besien KV, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001;19:1855–1864.CrossRefPubMedGoogle Scholar
  6. 6.
    Falini B, Venturi S, Martelli M, et al. Mediastinal large B-cell lymphoma: clinical and immunohistologic findings in 18 patients treated with different third-generation regimens. Br J Haematol. 1995;89:780–789.CrossRefPubMedGoogle Scholar
  7. 7.
    Zinzani PL, Martelli M, Bertini M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87:1258–1264.PubMedGoogle Scholar
  8. 8.
    Zinzani PL, Martelli M, Magagnoli M, et al. Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67) gallium scan in 50 patients. Blood. 1999;94:3289–3293.PubMedGoogle Scholar
  9. 9.
    Bieri S, Roggero E, Zucca E, et al. Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials. Leuk Lymphoma. 1999;35:139–146.CrossRefPubMedGoogle Scholar
  10. 10.
    Haioun C, Gaulard P, Roudot-Thoraval F, et al. Mediastinal diffuse large-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol. 1989;12:425–429.CrossRefPubMedGoogle Scholar
  11. 11.
    Jacobson JO, Aisenberg AC, Lamarre L, et al. Mediastinal large cell lymphoma. an uncommon subset of adult lymphoma curable with combined modality therapy. Cancer. 1988;62:1893–1898.CrossRefPubMedGoogle Scholar
  12. 12.
    Kirn D, Mauch P, Shaffer K, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993;11:1336–1343.CrossRefPubMedGoogle Scholar
  13. 13.
    Abou-Elella AA, Weisenburger DD, Vose JM, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. J Clin Oncol. 1999;17:784–790.CrossRefPubMedGoogle Scholar
  14. 14.
    Yonetani N, Kurata M, Nishikori M, et al. Primary mediastinal large B-cell lymphoma: a comparative study with nodular sclerosistype Hodgkin’s disease. Int J Hematol. 2001;74:178–185.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nakagawa A, Nakamura S, Koshikawa T, et al. Clinicopathologic study of primary mediastinal non-lymphoblastic non-Hodgkin’s lymphomas among the Japanese. Acta Pathol Jpn. 1993;43:44–54.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Itami J, Hara R, Komiyama T, et al. Role of radiation therapy in the management of primary mediastinal large B-cell lymphoma (PMLBL). Rad Med. 2002;20:311–318.Google Scholar
  17. 17.
    Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–862.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871–3879.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lossos IS, Levy R. Diffuse large B-cell lymphoma: insights gained from gene expression profiling. Int J Hematol. 2003;77:321–329.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kadin ME, Berard CW, Nanba K, Wakasa H. Lymphoproliferative diseases in Japan and Western countries: proceedings of the United States-Japan Seminar, September 6 and 7, 1982, in Seattle, Washington. Hum Pathol. 1983;14:745–772.CrossRefPubMedGoogle Scholar
  21. 21.
    International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994.CrossRefGoogle Scholar
  22. 22.
    Green FL, Page DL, Fleming ID, et al., eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002:393–403.CrossRefGoogle Scholar
  23. 23.
    Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1861.PubMedGoogle Scholar
  24. 24.
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Lister TA, Crowther D, Sutcliffe SB, et al. Report of committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds Meeting. J Clin Oncol. 1989;7:1630–1636.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Shimoyama M, Ota K, Kikuchi M, et al. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin’s lymphoma treated with VEPA or VEPA-M. J Clin Oncol. 1988;6:128–141.CrossRefPubMedGoogle Scholar
  27. 27.
    Tobinai K, Shimoyama M, Minato K, et al. Japan Clinical Oncology Group phase II trial of second-generation “LSG4 protocol” in aggressive T- and B-lymphoma: a new predictive model for T- and B-lymphoma [abstract]. Proc Am Soc Clin Oncol. 1994;13:378.Google Scholar
  28. 28.
    Kinoshita T, Hotta T, Tobinai K, et al. Randomized phase III trial investigating survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediateor high-grade non-Hodgkin’s lymphoma (NHL): Japan Clinical Oncology Group (JCOG) Study (JCOG9002) [abstract]. Proc Am Soc Clin Oncol. 2002;21:289a.Google Scholar
  29. 29.
    Lamarre L, Jacobson JO, Aisenberg AC, Harris NL. Primary large cell lymphoma of the mediastinum: a histologic and immunophenotypic study of 29 cases. Am J Surg Pathol. 1989;13:730–739.CrossRefPubMedGoogle Scholar
  30. 30.
    Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–3918.Google Scholar
  31. 31.
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes: Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–2795.CrossRefPubMedGoogle Scholar
  32. 32.
    Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol. 1998;9:717–720.CrossRefPubMedGoogle Scholar
  33. 33.
    Toh HC, Koh CH, Ang PT. Primary mediastinal large cell lymphoma in an aggressive and chemorefractory subtype in an Asian diffuse large cell lymphoma series. Med Pediatr Oncol. 1998;31:125.CrossRefPubMedGoogle Scholar
  34. 34.
    Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50:696–702.CrossRefGoogle Scholar
  35. 35.
    Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985;102:596–602.CrossRefPubMedGoogle Scholar
  36. 36.
    Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood. 1998;91:717–723.PubMedGoogle Scholar
  37. 37.
    Popat U, Przepiorka D, Champlin R, et al. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts a favorable prognosis. J Clin Oncol. 1998;16:63–69.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Naohiro Sekiguchi
    • 1
  • Junko Nishimoto
    • 1
  • Kazuki Tanimoto
    • 1
  • Shigeru Kusumoto
    • 1
  • Yasushi Onishi
    • 1
  • Takashi Watanabe
    • 1
  • Yukio Kobayashi
    • 1
  • Hisao Asamura
    • 2
  • Yoshikazu Kagami
    • 3
  • Yoshihiro Matsuno
    • 4
  • Kensei Tobinai
    • 1
  1. 1.HematologyNational Cancer Center HospitalTokyoJapan
  2. 2.Thoracic SurgeryNational Cancer Center HospitalTokyoJapan
  3. 3.Radiation OncologyNational Cancer Center HospitalTokyoJapan
  4. 4.Clinical Laboratory DivisionsNational Cancer Center HospitalTokyoJapan

Personalised recommendations